Performance of Newer Myeloma Staging Systems in a Contemporary, Large Patient Cohort

Overview

Journal Blood Cancer J

Date 2024 Jun 11

PMID 38862493

Authors

Ghulam Rehman Mohyuddin

Samuel M Rubinstein

Shaji Kumar

S Vincent Rajkumar

Rafael Fonseca

Nadine H Abdallah

Gregory S Calip

Xiaoyan Wang

Christina M Parrinello

Douglas Sborov

Affiliations

Soon will be listed here.

Citing Articles

High WEE1 expression is independently linked to poor survival in multiple myeloma.

Simhal A, Firestone R, Oh J, Avutu V, Norton L, Hultcrantz M Blood Cancer J. 2025; 15(1):22.

PMID: 39979284 PMC: 11842801. DOI: 10.1038/s41408-025-01230-y.

High WEE1 expression is independently linked to poor survival in multiple myeloma.

Simhal A, Firestone R, Oh J, Avutu V, Norton L, Hultcrantz M bioRxiv. 2024; .

PMID: 39386721 PMC: 11463642. DOI: 10.1101/2024.09.20.613788.

References

Walker B, Mavrommatis K, Wardell C, Ashby T, Bauer M, Davies F . A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2018; 33(1):159-170. PMC: 6326953. DOI: 10.1038/s41375-018-0196-8. View

DAgostino M, Cairns D, Lahuerta J, Wester R, Bertsch U, Waage A . Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. J Clin Oncol. 2022; 40(29):3406-3418. DOI: 10.1200/JCO.21.02614. View

Schavgoulidze A, Lauwers-Cances V, Perrot A, Cazaubiel T, Chretien M, Moreau P . Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma. Haematologica. 2022; 108(5):1374-1384. PMC: 10153521. DOI: 10.3324/haematol.2021.280566. View

Yan W, Fan H, Xu J, Liu J, Li L, Du C . Prognostic value of the Second Revision of the International Staging System (R2-ISS) in a real-world cohort of patients with newly-diagnosed multiple myeloma. Chin Med J (Engl). 2023; 136(14):1744-1746. PMC: 10344481. DOI: 10.1097/CM9.0000000000002735. View

Mizuguchi M, Okamoto Y, Yagi H, Kagawa K, Sekimoto E, Shibata H . Clinical relevance of high-risk cytogenetic abnormalities and the second revision of the International Staging System (R2-ISS) in patients with multiple myeloma in clinical practice. Int J Hematol. 2023; 117(5):718-728. DOI: 10.1007/s12185-023-03541-x. View

Cao Y, Gong Y, Zhou X, Sun C . Prognostic evaluation and staging optimization of the Mayo Additive Staging System (MASS) in real world for newly diagnosed multiple myeloma patients. Hematology. 2023; 28(1):2208914. DOI: 10.1080/16078454.2023.2208914. View

Chen H, Zhou N, Hu X, Wang D, Wei W, Peng R . The applicability of the Second Revision of the International Staging System for patients with multiple myeloma receiving immunomodulatory drugs or proteasome inhibitor-based regimens as induction treatment: A real-world analysis. Hematol Oncol. 2022; 41(1):139-146. DOI: 10.1002/hon.3090. View

Guo W, Zhan A, Mery D, Munshi M, Makhoul O, Baily C . Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS. Blood Adv. 2023; 7(21):6676-6684. PMC: 10637884. DOI: 10.1182/bloodadvances.2023011096. View

Schmidt T, Barwick B, Joseph N, Heffner L, Hofmeister C, Bernal L . Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood Cancer J. 2019; 9(12):94. PMC: 6877577. DOI: 10.1038/s41408-019-0254-0. View

10.

Thorsteinsdottir S, Dickman P, Landgren O, Blimark C, Hultcrantz M, Turesson I . Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. Haematologica. 2018; 103(9):e412-e415. PMC: 6119139. DOI: 10.3324/haematol.2017.183475. View

11.

Weinhold N, Salwender H, Cairns D, Raab M, Waldron G, Blau I . Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients. Haematologica. 2021; 106(10):2754-2758. PMC: 8485656. DOI: 10.3324/haematol.2021.278888. View

12.

Abdallah N, Binder M, Rajkumar S, Greipp P, Kapoor P, Dispenzieri A . A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer J. 2022; 12(1):21. PMC: 8803917. DOI: 10.1038/s41408-022-00611-x. View

13.

Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst H, Goldschmidt H, Rosinol L . Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015; 33(26):2863-9. PMC: 4846284. DOI: 10.1200/JCO.2015.61.2267. View